VERU Stock — Veru Inc.: Cash, EV, Pipeline

What they do

We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin.

Source: 10-K FY2025 via SEC EDGAR

Share price

$2.12

Market cap

$36.1M

Cash

$23.9M

Enterprise value

$12.2M

Balance sheet

Cash	$23.9M
Debt	$0.0M
Net cash	$23.9M
Enterprise value	$12.2M
Basic shares	17.1M shares
Fully diluted shares	22.5M shares
Fully diluted market cap	$47.7M
Cash per share	$1.40
Quarterly burn	$5.5M
Cash runway	4.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

17.1M

Pre-funded warrants

0.0M

Options

4.4M

RSUs

0.0M

Warrants

0.8M

Converts

0.1M

Conv preferred

0.0M

ESPP reserve

—

FDSO

22.5M

Cap table as of 2026-08-06.

Price history

Loading VERU daily closes…

Loading price history…

Next catalyst

enobosarm · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	enobosarm PLATEAU Phase 3b trial of enobosarm: interim DXA body-composition analysis	Phase 3b	Not disclosed	Q1 2027
GUIDEDEst. Nov 15, 2027 in 11 mo quarter midpoint	enobosarm PLATEAU Phase 3b trial of enobosarm: final topline clinical data	Phase 3b	Not disclosed	Q4 2027
Nov 12 - Dec 24 in 12 mo	Enobosarm	Phase 2	Obesity & Overweight; Mobility Disability; HOMA-IR	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Enobosarm

Phase 2 · Active Modality: oral selective androgen receptor modulator (SARM)

Target androgen receptor

Partnerships Novo Nordisk (clinical supply agreement for Wegovy, June 2026)

Indications

obesity (augment fat loss and preserve muscle with GLP-1 RA therapy) (Phase 2)

Status note PLATEAU Phase 2b ongoing with Wegovy; QUALITY Phase 2b completed.

Sabizabulin

Preclinical · Active Modality: oral broad anti-inflammatory agent

Target microtubules

Indications

atherosclerotic cardiovascular disease (Preclinical)

Status note Planned Phase 2 for inflammation in atherosclerotic cardiovascular disease; no active new-indication trial per filing.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Enobosarm
Lead indication	Obesity & Overweight
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07446998	Phase 2	Active, not recruiting	Sponsor	VERU	—	Obesity & Overweight; Mobility Disability; HOMA-IR	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Veru Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	35,000	no change	0.01%	2026-08-14
Ikarian Capital	0	-133,517	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

VERU — Veru Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

VERU — Veru Inc.